CUSIP: 10919W405
Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
7,758,356
-
Total 13F shares
-
6,590,203
-
Share change
-
+528,534
-
Total reported value
-
$514,917,301
-
Price per share
-
$78.04
-
Number of holders
-
74
-
Value change
-
+$43,333,109
-
Number of buys
-
43
-
Number of sells
-
27
Quarterly Holders Quick Answers
What is CUSIP 10919W405?
CUSIP 10919W405 identifies DRUG - BRIGHT MINDS BIOSCIENCES INC. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Previous quarter:
Q3 2025
Recent filing periods for CUSIP 10919W405:
Institutional Holders of BRIGHT MINDS BIOSCIENCES INC. - Common Stock (DRUG) as of Q4 2025
As of 31 Dec 2025,
BRIGHT MINDS BIOSCIENCES INC. - Common Stock (DRUG) was held by
74 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,590,203 shares.
The largest 10 holders included
JANUS HENDERSON GROUP PLC, Cormorant Asset Management, LP, Vivo Capital, LLC, PERCEPTIVE ADVISORS LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., BlackRock, Inc., BRAIDWELL LP, Driehaus Capital Management LLC, MPM BIOIMPACT LLC, and Balyasny Asset Management L.P..
This page lists
74
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.